**Supplemental Table 1.** Factors associated with 1L CT useover time.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **August to December 2018** | **January to June 2019** | **July to December 2019** |
|  | **Odds ratio** | **95% CI** | **p value** | **Odds ratio** | **95% CI** | **p value** | **Odds ratio** | **95% CI** | **p value** |
| Age category, years<65 65–75 >75  | ref1.011.01 | –0.73–1.410.70–1.46 | –0.930.95 | ref0.701.03 | –0.50–0.990.72–1.49 | –0.050.87 | ref0.990.78 | –0.71–1.380.52–1.16 | –0.940.22 |
| GenderFemaleMale  | ref0.86 | –0.65–1.16 | –0.32 | ref0.82 | –0.62–1.09 | –0.17 | ref1.02 | –0.75–1.37 | –0.92 |
| Race WhiteBlackAsianOtherUnknown | ref0.932.591.281.66 | –0.55–1.570.87–7.690.78–2.101.11–2.49 | –0.780.090.320.01 | ref1.021.450.770.75 | –0.63–1.680.46–4.620.45–1.320.47–1.20 | –0.920.530.340.23 | ref1.181.271.020.90 | –0.70–1.970.35–4.570.63–1.640.57–1.42 | –0.530.710.940.66 |
| RegionSouthNortheastWestMidwestPuerto RicoUnknown | ref0.910.940.790.002.12 | –0.62–1.330.59–1.490.50–1.220.00–NE0.34–13.06 | –0.610.780.280.970.42 | ref0.530.880.813.161.21 | –0.35–0.830.56–1.400.53–1.240.80–12.470.24–6.24 | –<0.010.600.330.100.82 | ref0.841.071.330.001.11 | –0.55–1.290.67–1.700.88–2.020.00–NE0.62–2.01 | –0.430.780.180.980.72 |
| Practice setting Academic\*Community | ref2.47 | –0.37–16.44 | –0.35 | ref1.12 | –0.20–6.22 | –0.90 | –– | –– | –– |
| ECOG performance status01≥2Unknown | ref1.270.871.17 | –0.86–1.860.55–1.370.75–1.84 | –0.230.550.48 | ref0.650.820.82 | –0.44–0.950.54–1.260.53–1.28 | –0.020.370.39 | ref0.870.690.77 | –0.59–1.270.43–1.100.48–1.24 | –0.470.120.28 |
| Diagnosis to index date period, months0–1 1–2 2–3 >3  | ref1.020.901.16 | –0.74–1.410.54–1.520.75–1.81 | –0.890.700.50 | ref0.811.431.78 | –0.58–1.130.91–2.241.14–2.77 | –0.210.120.01 | ref0.971.451.14 | –0.69–1.380.91–2.330.70–1.84 | –0.880.120.60 |
| Smoking statusNo history of smokingHistory of smoking | ref1.31 | –0.76–2.26 | –0.34 | ref1.26 | –0.76–2.11 | –0.37 | ref1.43 | –0.81–2.52 | –0.22 |
| Histology Non-squamousSquamousNot otherwise specified | ref2.861.08 | –2.08–3.930.57–2.05 | –<0.010.81 | ref1.882.11 | –1.37–2.601.14–3.91 | –<0.010.02 | ref1.521.01 | –1.08–2.140.47–2.16 | –0.020.98 |
| PD-L1 expression 50%–100%<1%1%–49%Unknown | ref3.462.112.64 | –2.28–5.241.34–3.311.74–4.01 | –<0.01<0.01<0.01 | ref3.592.544.42 | –2.29–5.641.60–4.042.82–6.92 | –<0.01<0.01<0.01 | ref2.241.302.02 | –1.48–3.390.84–2.021.32–3.10 | –<0.010.23<0.01 |
| Brain metastasesPresenceAbsence  | ref0.88 | –0.58–1.33 | –0.54 | ref1.02 | –0.66–1.58 | –0.93 | ref0.90 | –0.60–1.37 | –0.63 |

\*Practice setting was not included in the July through December 2019 model because it was perfectly identified by Region = “Unknown”.

1L: first-line; CI: confidence interval; CT: chemotherapy; ECOG: Eastern Cooperative Oncology Group; NE: not estimable; PD-L1: programmed death ligand-1.